Video

Dr. Dreicer on Prostate Cancer Combination Therapy

Author(s):

Robert Dreicer, MD

Robert Dreicer, MD, from the Taussig Cancer Institute, discusses the various treatments that prostate cancer patients may receive in combination.

Robert Dreicer, MD, from the Taussig Cancer Institute, discusses the various treatments that prostate cancer patients may receive in combination. He describes that although they have not be studied in combination some of these drugs will most likely overlap or be used together even though data is not available to see what type of reaction it will create.

Related Videos
Nitin Jain, MD
Kimmie Ng, MD, MPH
Marina Chiara Garassino, MD
Elias Jabbour, MD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Rahul Banerjee, MD, FACP
Seth Wander, MD, PhD
Piotr Rutkowski, MD
Javier Martín Broto MD, PhD
Nicolas Girard, MD
Thach-Giao Truong, MD, medical director, Melanoma Program, Cleveland Clinic
Related Content
Neal Shore, MD, FACS, steering committee chair, medical director, Carolina Urologic Research Center
October 9th 2024

Apalutamide Demonstrates Real-World OS Benefit vs Enzalutamide in mCSPC

Neeraj Agarwal, MD
July 17th 2023

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

Neeraj Agarwal, MD, FASCO
October 8th 2024

PARP1-Selective Inhibitors Generate Excitement in Solid Tumors

Andrew J. Armstrong, MD, MSc
June 15th 2023

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

Bertram Yuh, MD, MISM, MSHCPM
September 30th 2024

Prostate Cancer Awareness Efforts Target Patient Education, Treatment Access, and Survivorship Care

Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
September 26th 2024

sNDA for Darolutamide Plus ADT in mHSPC Submitted for FDA Review